The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFD Technologies Regulatory News (FDP)

Share Price Information for FD Technologies (FDP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,352.00
Bid: 1,340.00
Ask: 1,352.00
Change: 0.00 (0.00%)
Spread: 12.00 (0.896%)
Open: 1,330.00
High: 1,378.00
Low: 1,324.00
Prev. Close: 1,352.00
FDP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

9 Apr 2020 07:00

RNS Number : 2822J
First Derivatives PLC
09 April 2020
 

9 April 2020

 

First Derivatives plc

("FD" or the "Group")

 

Trading Update and Notice of Results

 

FD (AIM: FDP.L, Euronext Growth: FDP.I) announces that it continued to trade positively in the second half of the financial year ended 29 February 2020. As a result, the Board expects to report a financial performance in line with company-compiled consensus forecasts of £241m of revenue and £46m of adjusted EBITDA. Net debt at the period end was £50m, which was better than the consensus forecast of £56m.

 

COVID-19

 

The global operations of the Group enabled us to identify the business disruption threat of COVID-19 early, and we implemented our pandemic plan at the beginning of February across all regions in which we operate. A team led by CEO Seamus Keating and comprising senior leaders across FD coordinated the action, with the priorities of protecting the health and wellbeing of our employees and supporting our customers.

 

In FinTech, the Group supports mission-critical systems across the financial industry and in other markets our technology is key to the success of our customers. We contacted all our customers to minimise the impact of COVID-19 through various measures including remote working and are pleased that these are working without significant disruption to the business.

 

Impact to date

 

To date we have seen no financial impact from the effects of COVID-19. All our services delivery is now being conducted remotely, with no impact on revenue. In our managed services and consulting business the services that we provided prior to COVID-19 are now being delivered remotely with utilisation rates in March 2020 remaining in line with the prior month. We continue to monitor developments closely through close and regular contact with customers across all the markets in which we operate.

 

Potential impacts and mitigation

 

Looking ahead, our conversations with customers indicate that in the near-term there will be a lengthening of software sales cycles, at least until the impact of COVID-19 is clearer. The Group is protected to some extent by the breadth of its sales pipeline across multiple industries and geographies, while further reassurance is provided by the repeat and recurring nature of the majority of our software revenue.

 

In consulting and managed services, we continue to benefit from high levels of repeat revenue from the 'Business as Usual' operations of our capital markets clients. We are monitoring the impact of COVID-19 on new business, particularly with regard to project work implementing change programs.

 

As the macroeconomic impact of COVID-19 continues to grow, the Group has conducted a scenario testing exercise with a range of assumptions including a severe, extended downturn in economic activity. Under all such scenarios the Group remains profitable and cash generative.

 

Notwithstanding the assurance provided by our scenario testing, the Group has taken a range of measures to mitigate any future potential impact of COVID-19, including suspending non-essential business travel and short-term deferral of the summer graduate intake. In addition, the Executive Directors will not receive a bonus payment relating to the financial year ended 29 February 2020.

 

In order to preserve the Group's liquidity during this period, the Board will not recommend a final dividend in respect of the year to 29 February 2020.

 

Liquidity

 

As at 31 March 2020, FD had gross cash available to it of £64m. This included £35m of funds drawn down on 24 March 2020 from the Group's available finance facilities, with the funds placed on deposit to provide further comfort on liquidity should conditions deteriorate markedly. The Group has a further £15m in undrawn revolving credit facilities available to it.

 

The Group has significant headroom on its covenants and taking into account the scenario testing and mitigating measures taken, expects that situation to persist through the impact of COVID-19, irrespective of its duration.

 

The strength of our business model and liquidity position provide us with the confidence to continue to invest across the Group, in line with our strategy.

 

Summary

 

The Group delivered continued solid growth in the financial year to 29 February 2020. We reacted quickly to help employees and customers minimise the impact of COVID-19. While there has been no financial impact to date, it is still too early to determine what impact may result, particularly if there is an extended period of economic disruption. We believe that the Group has acted prudently to mitigate any potential impact through a range of measures aimed at ensuring its ongoing financial liquidity.

 

In the longer term, FD remains confident in its strategy and in particular the growth in demand for its world-class Kx technology from both potential customers and partners.

 

Date of results

 

The Group will announce its full year results for the year ended 29 February 2020 on 19 May 2020. A briefing for analysts and investors will be held on the day and further details will be provided in due course.

 

Enquiries

For further information please contact:

 

First Derivatives plc

Seamus Keating, Chief Executive Officer

Graham Ferguson, Chief Financial Officer

Ian Mitchell, Head of Investor Relations

+44(0)28 3025 2242

www.firstderivatives.com

 

 

Investec Bank plc (Nominated Adviser and Broker)

Andrew Pinder

Carlton Nelson

Sebastian Lawrence

+44 (0)20 7597 5970

 

 

Goodbody (Euronext Growth Adviser and Broker)

David Kearney

Don Harrington

Finbarr Griffin

 

+353 1 667 0420

 

 

 

FTI Consulting

Matt Dixon

Dwight Burden

Darius Alexander

 

+44 (0)20 3727 1000

 

 

About FD

FD is a global technology provider with more than 20 years of experience working with some of the world's largest finance, technology, automotive, utility, manufacturing and energy institutions. The Group's Kx technology, incorporating the kdb+ time-series database, is a leader in high-performance, in-memory computing, streaming analytics and operational intelligence. Kx delivers the best possible performance and flexibility for high-volume, data-intensive analytics and applications across multiple industries. FD operates from 15 offices across Europe, North America and Asia Pacific, including its headquarters in Newry, and employs more than 2,400 people worldwide.

 

For further information, please visit www.firstderivatives.com and www.kx.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTFLFERSRITIII
Date   Source Headline
2nd Jun 20179:56 amRNSAnnual Report 2016/17 and AGM Notice
30th May 20175:13 pmRNSDirector/PDMR Shareholding
30th May 20175:12 pmRNSDirector/PDMR Shareholding
30th May 20172:06 pmRNSIssue of Equity from exercise of Share Options
16th May 20177:00 amRNSFinal Results
15th May 20175:09 pmRNSAppointment and Directorate Change
24th Apr 20177:00 amRNSTrading Update and Notice of Results
3rd Apr 201710:28 amRNSTotal Voting Rights
20th Mar 20177:00 amRNSEnterprise Securities Market Notice
14th Mar 20174:39 pmRNSIssue of Equity
14th Mar 20177:00 amRNSCollaboration Agreement with Airbus
2nd Mar 20177:00 amRNSContract Win
28th Feb 201710:09 amRNSTotal Voting Rights
7th Feb 20177:00 amRNSEnterprise Securities Market Notice
1st Feb 20173:54 pmRNSIssue of Equity
30th Dec 201610:57 amRNSTotal Voting Rights
23rd Dec 20167:00 amRNSEnterprise Securities Market Notice
19th Dec 20164:06 pmRNSIssue of Equity
7th Dec 20161:26 pmRNSHolding(s) in Company
7th Dec 20167:00 amRNSEnterprise Securities Market Notice
1st Dec 20164:52 pmRNSIssue of Equity from exercise of Share Options
30th Nov 201612:21 pmRNSTotal Voting Rights
8th Nov 20167:00 amRNSEntry into Retail Analytics market
8th Nov 20167:00 amRNSEnterprise Securities Market Notice
3rd Nov 20164:21 pmRNSDirector/PDMR Shareholding
3rd Nov 20164:20 pmRNSDirector/PDMR Shareholding
3rd Nov 20164:19 pmRNSDirector/PDMR Shareholding
1st Nov 20166:13 pmRNSIssue of Equity
1st Nov 20167:00 amRNSHalf Yearly Report
19th Oct 20167:00 amRNSNotice of Interim Results
30th Sep 20169:53 amRNSTotal Voting Rights
14th Sep 20167:00 amRNSEnterprise Securities Market Notice
7th Sep 20162:15 pmRNSIssue of Equity from exercise of Share Options
29th Jul 20161:29 pmRNSTotal Voting Rights
20th Jul 20164:59 pmRNSDirector Shareholding - AMENDMENT
19th Jul 20165:03 pmRNSDirector Shareholding
12th Jul 20167:00 amRNSDirector/PDMR Shareholding
30th Jun 20168:05 amRNSTotal Voting Rights
23rd Jun 20162:06 pmRNSResult of AGM
15th Jun 20167:00 amRNSDirector/PDMR Shareholding
6th Jun 201612:00 pmRNSIssue of Equity from exercise of Share Options
3rd Jun 20163:45 pmRNSAnnual Report 2015/16 and AGM Notice
19th May 20165:11 pmRNSHolding(s) in Company
17th May 20167:00 amRNSFinal Results
13th May 20164:38 pmRNSDirectorate Change
27th Apr 20167:00 amRNSStrategic Partnership with Thomson Reuters
26th Apr 20167:00 amRNSNotice of Results
4th Apr 20167:00 amRNSTrading Update
31st Mar 20164:44 pmRNSTotal Voting Rights
7th Mar 20167:00 amRNSEnterprise Securities Market Notice

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.